HanchorBio Inc.

As of June 30, 2026, HanchorBio Inc. carries a market capitalization of 24.21B, placing it among publicly traded companies globally. Its enterprise value stands at 22.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HanchorBio Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, HanchorBio Inc. has 139.97M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 69.28, and the price-to-book ratio stands at 18.27.

These figures are as of June 30, 2026. The EV/Sales ratio of 70.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 22.74B versus a market cap of 24.21B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, HanchorBio Inc. maintains a current ratio of 4.09, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.54, indicating elevated leverage, while an interest coverage ratio of -211.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, HanchorBio Inc. posted a negative return on equity (ROE) of -86.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.74, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, HanchorBio Inc. recorded 32.07M in income tax expense. The company reported a pretax loss of -722.42M and -572.58M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, HanchorBio Inc. generated 321.77M in revenue and converted that into -572.58M in net income, yielding earnings per share of -5.83. EBITDA reached -685.46M, while operating income came in at -724.62M.

As of June 30, 2026, HanchorBio Inc. holds 1.76B in cash and equivalents against 140.12M in total debt, resulting in a net debt position of -1.66B. Total book value stands at 1.33B, with working capital of 1.38B providing operational flexibility.

HanchorBio Inc. produced -515.28M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -24.46M in capital expenditures, free cash flow totaled -539.74M - equivalent to -4.19 per share.

Over the twelve months ended June 30, 2026, HanchorBio Inc. posted a gross margin of 97.23, reflecting its pricing power and cost economics. The operating margin of -225.20 and net profit margin of -177.95 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.06, meaning HanchorBio Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HanchorBio Inc.'s most recent stock split took place on September 2, 2025.

As of June 30, 2026, HanchorBio Inc. has an Altman Z-Score of 27.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.